CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) had its price target raised by Stifel Nicolaus from $27.00 to $30.00 in a report released on Monday. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Ladenburg Thalmann lifted their target price on shares of CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the company a buy rating in a research note on Tuesday, September 6th. Piper Jaffray Cos. reiterated a buy rating and issued a $36.00 target price on shares of CoLucid Pharmaceuticals in a research note on Thursday, September 15th. Finally, Zacks Investment Research upgraded shares of CoLucid Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, May 31st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $30.45.

CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 31.06 on Monday. The firm’s 50-day moving average is $15.26 and its 200 day moving average is $9.18. The firm’s market capitalization is $476.27 million. CoLucid Pharmaceuticals has a one year low of $3.57 and a one year high of $35.48.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. Analysts forecast that CoLucid Pharmaceuticals will post ($3.91) EPS for the current fiscal year.

In other news, CEO Thomas P. Mathers sold 6,000 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $23.32, for a total value of $139,920.00. Following the completion of the sale, the chief executive officer now directly owns 244,714 shares in the company, valued at $5,706,730.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the business’s stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total transaction of $1,293,086.60. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Societe Generale purchased a new stake in shares of CoLucid Pharmaceuticals during the second quarter worth $464,000. FMR LLC bought a new position in shares of CoLucid Pharmaceuticals during the second quarter worth about $554,000. Finally, Vanguard Group Inc. raised its position in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the period. Institutional investors and hedge funds own 36.92% of the company’s stock.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.